Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023:   Further strong growth and doubling of the operating result
EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023): https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced

Simulations Plus Outlines Paths to Win at 2023 Investor Day: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Outlines Paths to Win at 2023 Investor Day


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today will host its investor

EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO


Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin

EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
Inogen to Present at Upcoming Investor Conferences in November 2023: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Present at Upcoming Investor Conferences in November 2023


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following

NanoString to Webcast Presentations from Upcoming Healthcare Conferences: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentations from Upcoming Healthcare Conferences


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast

ISoP New Board of Trustees Members Announced: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
ISoP New Board of Trustees Members Announced


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña, Vice

Inogen Announces Third Quarter 2023 Financial Results: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces Third Quarter 2023 Financial Results


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September

NanoString Technologies Releases Operating Results for Third Quarter of 2023: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Releases Operating Results for Third Quarter of 2023


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended

Owens & Minor Reports Third Quarter 2023 Financial Results: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Reports Third Quarter 2023 Financial Results


Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2023.



Third Quarter Key Highlights:




  • Consolidated revenue of $2.59 billion


  • Net

STAAR Surgical Reports Third Quarter 2023 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Third Quarter 2023 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported

Simulations Plus to Host Investor Day on Tuesday, November 14th: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Host Investor Day on Tuesday, November 14th


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods

Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its

Owens & Minor Announces Third Quarter 2023 Earnings Release Date and Conference Call: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Announces Third Quarter 2023 Earnings Release Date and Conference Call


Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the third quarter of 2023 on Friday, November 3, 2023, before trading begins on the New York Stock Exchange.



The Company

Owens & Minor Announces Third Quarter 2023 Earnings Release Date and Conference Call: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Announces Third Quarter 2023 Earnings Release Date and Conference Call


Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the third quarter of 2023 on Friday, November 3, 2023, before trading begins on the New York Stock Exchange.



The Company

EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
STAAR Surgical to Report Third Quarter Results on November 1, 2023: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report Third Quarter Results on November 1, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter

EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL): https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer®

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25